In Brief: Eclipse Surgical Technologies
This article was originally published in The Gray Sheet
Executive SummaryEclipse Surgical Technologies: Inks deal with Saluggia, Italy-based Sorin Biomedica Cardio, S.p.A. under which Sorin agrees to purchase at least 30 of Eclipse's laser-based transmyocardial revascularization (TMR) systems by Dec. 31, 1997, for marketing outside the U.S. Eclipse currently is engaged in clinical trials for its TMR system to treat patients with severe angina ("The Gray Sheet" Feb. 12, p. 12)...
You may also be interested in...
ConMed's CFO Todd Garner told delegates at the Jefferies Healthcare conference that the company's orthopedic franchise is focused on its pipeline and meeting customer's needs. See what the CFO said about it here.
Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.
Correvio’s attempt to move vernakalant from 'clinical hold' to 'FDA approved' was a huge long shot. But the advisory committee vote – and looming FDA rejection – are another indication that real-world data is not a panacea.